Dual roles of endothelial FGF-2–FGFR1–PDGF-BB and perivascular FGF-2–FGFR2–PDGFRβ signaling pathways in tumor vascular remodeling

Endocrine vasculatures are preferable targets of an antitumor ineffective low dose of anti-VEGF therapy

(2016) Yin Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pericyte–fibroblast transition promotes tumor growth and metastasis

(2016) Kayoko Hosaka et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

La signalisation FGF/FGFR : implication dans l’oncogenèse et perspectives thérapeutiques

(2015) Ronan Flippot et al.   BULLETIN DU CANCER

PlGF-induced VEGFR1-dependent vascular remodeling determines opposing antitumor effects and drug resistance to Dll4-Notch inhibitors

(2015) H. Iwamoto et al.   Science Advances

VEGFR2-Mediated Vascular Dilation as a Mechanism of VEGF-Induced Anemia and Bone Marrow Cell Mobilization

(2014) Sharon Lim et al.   Cell Reports

Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues

(2013) Y. Yang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Multifarious functions of PDGFs and PDGFRs in tumor growth and metastasis

(2013) Yihai Cao   TRENDS IN MOLECULAR MEDICINE

Structural and Functional Properties of Platelet-Derived Growth Factor and Stem Cell Factor Receptors

(2013) C.-H. Heldin et al.   Cold Spring Harbor Perspectives in Biology

Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets

(2012) Simon Wöhrle et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF–VEGFR2 signalling

(2012) Rui Benedito et al.   NATURE

Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis

(2012) R. Cao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tumor cell-derived placental growth factor sensitizes antiangiogenic and antitumor effects of anti-VEGF drugs

(2012) E.-M. E. Hedlund et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor

(2012) V. Guagnano et al.   Cancer Discovery

Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase

(2011) Vito Guagnano et al.   JOURNAL OF MEDICINAL CHEMISTRY

PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells

(2011) Yuan Xue et al.   NATURE MEDICINE

Synergistic effects of FGF-2 and PDGF-BB on angiogenesis and muscle regeneration in rabbit hindlimb ischemia model

(2010) Jie Li et al.   MICROVASCULAR RESEARCH

The FGF family: biology, pathophysiology and therapy

(2009) Andrew Beenken et al.   NATURE REVIEWS DRUG DISCOVERY

Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature

(2009) E.-M. Hedlund et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

VEGFR1-mediated pericyte ablation links VEGF and PlGF to cancer-associated retinopathy

(2009) R. Cao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance

(2009) Yihai Cao et al.   SEMINARS IN CANCER BIOLOGY

R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways

(2008) Yihai Cao et al.   JOURNAL OF MOLECULAR MEDICINE-JMM